Építés alatt – nem éles oldal
Belépés
Leállítva3. fázis

Azole-echinocandin Combination Therapy for Invasive Aspergillosis

A legfontosabb adatok

Ki végzi
Erasmus Medical Center
Hol
Belgium és Hollandia4 helyszín, 2 országbanVálassz országot a helyszínekhez
Állapot
Leállítva
Fázis
3. fázis
Résztvevők
66 fő vett részt
Kezdés
2021. máj. 11.
Befejezés
2024. máj. 1.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Azole
  • Anidulafungin
A regiszteradat frissítve
2024. május 7.
Miért állt le
futility

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 18 feltétel megnézéseKevesebb

Ki vehet részt

  • 18 years or older
  • Have started or will start voriconazole or isavuconazole (or posaconazole if voriconazole or isavuconazole cannot be given as per treating physician's decision) as antifungal therapy on the baseline visit
  • For all patients: presence of one of the EORTC/MSG host factors as defined in appendix 1 or being admitted to the ICU with influenza
  • For non-ICU patients or ICU patients without influenza: Meet the EORTC/MSG clinical criterium (appendix 1)
  • For non-ICU patients or ICU patients without influenza: Meet the mycological criterium (appendix 1) or fulfil inclusion criterium 7
  • For ICU patients with influenza we consider an isolated positive sputum culture for Aspergillus spp. insufficient as amycological criterium. Therefore, in these patients only one of the following mycological criteria are acceptable; Serum galactomannan ≥0.5, BAL galactomannan ≥1.0 or Aspergillus spp. cultured in BAL fluid
  • Please note that patients with AML receiving chemotherapy or patients with ALL receiving or having received corticosteroid therapy within the last 4 weeks in the context of their pre-phase, induction, consolidation, intensification or interphase treatment as well as patients receiving systemic immunosuppressive therapy for GVHD can be included before the mycological criterium is fulfilled on condition that they fulfill the EORTC/MSG lung CT radiology criteria (halo sign, well-described nodule, cavity as described in appendix 1) at the time of inclusion and as long as the mycological test results are expected to become available within 96 and no later than 7 days after inclusion. If these test results turn out to be negative, the patient will be withdrawn from the study and further treatment is at physician's discretion
  • Written informed consent by patient or legal representative

Ki nem vehet részt

  • Receipt of systemic antifungal treatment with an echinocandin or an azole for the current episode of invasive aspergillosis for a duration of > 96 hours
  • Patient previously included in this study
  • Known history of allergy, hypersensitivity or serious reaction to azole or echinocandin antifungals
  • Patients with chronic invasive aspergillosis or a chronic non-invasive aspergillus infection (e.g. aspergilloma) defined as the clinical or radiological sign of infection being present for >28 days
  • ICU patients only: Patients with a sequential organ failure assessment (SOFA) score >11 at the time of screening for the study are excluded. If randomization is done >24 hours after screening the calculation should be repeated before the patient can be randomized (appendix 3)
  • Patients with any condition which, in the opinion of the investigator, could affect patient safety, preclude evaluation of response (e.g. because survival beyond 6 weeks is unlikely due to the underlying disease status)
  • Receipt of itraconazole, voriconazole, posaconazole or isavuconazole as prophylaxis for at least 7 days in the 14 days preceding the date of the first radiological signs of the Aspergillus infection. Patients in which the most recent serum level of the triazole given as prophylaxis was subtherapeutic can be included (*)
  • Receipt of echinocandin prophylaxis for >96 hours in the preceding 7 days
  • For patients in the Netherlands only: Diagnostic testing to exclude azole resistance will not be possible (sputum cultures are negative and BAL sampling will not be performed)
  • ICU patients only: Patients in which weaning from the ventilator or ECMO system is deemed unlikely due to irreversible lung damage

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

2 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goals of this study are 3-fold:

A teljes eredeti leírásKevesebb

First, the main study and the primary endpoint will evaluate if the overall mortality can be decreased with initial azole-echinocandin combination therapy compared with triazole monotherapy in patients with IA and documented voriconazole susceptibility.

Second, the study design described will also allow to study several other subpopulations; Indeed, the outcome of the following subgroups will be evaluated as well; a. Patients starting azole monotherapy but who switch to directed therapy when it has become clear that the infection is caused by an azole resistant A. fumigatus. b. patients in which eventually no resistance data become available in relation to the treatment they received.

Third, the study will evaluate what the outcome is of patients that turn out to be infected with a triazole resistant A. fumigatus who started with a triazole-echinocandin combination therapy.

A vizsgálat 2 csoportja

  • Azole monotherapyMár használt kezelés, összehasonlításként

    Azole monotherapy Voriconazole or isavuconazole or posaconazole will be dosed according to the SPC and according to the route of administration (IV or orally) that is preferred by the treating physician. However, the dose may be changed based on therapeutic drug monitoring levels according to the local standard of care.

    Kezelés: Azole

  • Azole + AnidulafunginA vizsgált kezelés

    Azole + Anidulafungin Voriconazole or isavuconazole or posaconazole will be dosed according to the SPC and according to the route of administration (IV or orally) that is preferred by the treating physician. However, the dose may be changed based on therapeutic drug monitoring levels according to the local standard of care. Anidulafungin (Ecalta) is available as an intravenous formulation only. It will be used at the licensed dose of a 200mg loading dose on day 1 and 100mg QD thereafter. No dose adjustment is needed in patients with renal or hepatic insufficiency of any grade.

    Kezelés: Azole és Anidulafungin

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Azole-echinocandin Combination Therapy for Invasive Aspergillosis A Randomized Pragmatic Superiority Trial
Publikációk
A regiszteradat frissítve
2024. május 7.